Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 423-428

  Brakemeier, Susanne ^a   Schweiger, Brunhilde ^b   Lachmann, Nils ^a   Glander, Petra ^a   Schönemann, Constanze ^a   Diekmann, Fritz ^a   Neumayer, Hans Hellmut ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

H1N1; HLA antibodies; transplantation; vaccination

Indexed keywords

HLA ANTIBODY; INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE;

ADULT; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; VACCINATION;

EID: 84856650237     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr278     Document Type: Review

References (32)

1. Vilchez RA, Mc Curry K, Dauber J et al. influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291 (Pubitemid 36330248)
2. Thompson WW, Shay DK, Weintraub E et al. influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-1340 (Pubitemid 39223224)
3. Kunisaki KM, Janoff EN. influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9: 493-504
4. Danzinger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl 4): S258-S262
5. Centre for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection-California, April-May, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 536-541
6. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302: 1872-1879
7. Pebody RG, McLean E, Zhao H et al. Pandemic influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill 2010; 15: 19571
8. World Health Organisation. WHO Recommendations on Pandemic (H1N1) 2009 Vaccines. Geneva, Switzerland, 2009 http://www.who.int/csr/disease/swineflu/ notes/h1n1-vaccine-20090713/en/index.html
9. Kumar D, Morris MI, Kotton CN et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10: 18-25
10. Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361: 2424-2435
11. Zhu FC, Wang H, Fang HH et al. Anovel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361: 2414-2423
12. Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375: 56-66
13. Scharpe J, Evenepoel P, Maes B et al. influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8: 332-337
14. Keshtkar-Jahromi M, Argani H, Rahnavardi M et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 2008; 28: 654-660 (Pubitemid 351832453)
15. Briggs WA, Rozek RJ, Migdal SD et al. influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann Intern Med 1980; 92: 471-477 (Pubitemid 10156687)
16. Birdwell KA, Ikizler MR, Sannella EC et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009; 54: 112-121
17. Cavdar C, Sayan M, Sifil A et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003; 37: 71-76 (Pubitemid 36246218)
18. Sanchez-Fructuoso AI, Prats D, Naranjo P et al. influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: my-cophenolate versus azathioprine. Transplantation 2000; 69: 436-439 (Pubitemid 30118129)
19. Smith KG, Isbel NM, Catton MG et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160-164 (Pubitemid 28033597)
20. World Health Organisation. WHO Pandemic 2009 (H1N1) Update 115. http://www.who.int/csr/disease/swineflu/updates/en/index.html (27 August 2010, date last accured)
21. Manuel O, Pascual M, Hoschler K et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in im-munocompromised patients. Clin Infect Dis 2011; 52: 248-256
22. Meyer S, Adam M, Schweiger B et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011; 91: 1031-1035
23. Candon S, Thervet E, Lebon P et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9: 2346-2354
24. Kimball P, Verbeke S, Flattery M et al. influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69: 2449-2451 (Pubitemid 30409021)
25. Danziger-Isakov L, Cherkassky L, Siegel H et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation 2010; 89: 838-844
26. Talbot HK, Keitel W, Cate TR et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008; 26: 4057-4061
27. Wehland M, Bauer S, Brakemeier S et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011; 21: 179-184
28. World Health Organisation. WHO Manual on Animal influenza Diagnosis and Surveillance (WHO/CDS/CSR/NCS/2002.5). http://www.who.int/vaccine-research/ diseases/influenza/WHO-manual-on- animal-diagnosis-and-surveillance-2002-5.pdf (September 2010, date last accessed)
29. Centre for Biologics Evaluation and Research. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic influenza Vaccines. Bethesda, MD: Food and Drug Administration; 2007
30. European Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for influenza Vaccines (CPMP/BWP/214/96). London, UK: European Agency for the Evaluation of Medicinal Products; 1997
31. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttrans-plant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513
32. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964: 204: 998-1000